Skip to main
NUVB

Nuvation Bio (NUVB) Stock Forecast & Price Target

Nuvation Bio (NUVB) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Nuvation Bio is positioned for success due to their differentiated and novel therapeutic candidates, including taletrectinib, Safusidenib, NUV-1511, and NUV-868. According to their financials, the company generates the majority of its revenue in Japan through out-licensing collaborative agreements, indicating strong partnerships and market potential. With a strong pipeline and positive clinical trial results, Nuvation Bio has the potential for significant growth in the targeted cancer therapy market. Overall, the company has a solid foundation and promising outlook for future success.

Bears say

Nuvation Bio is a biopharmaceutical company with a strong focus on developing novel therapeutic candidates for unmet needs in the oncology space. While their product candidate, taletrectinib, may have potential, the company's heavy reliance on out-licensing agreements for the majority of their revenue and the competitive landscape in the space may present challenges for their commercial success. Additionally, the early nature of their pipeline and potential delays in clinical trials could result in significant risks and delays for their lead programs.

Nuvation Bio (NUVB) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvation Bio (NUVB) Forecast

Analysts have given Nuvation Bio (NUVB) a Buy based on their latest research and market trends.

According to 9 analysts, Nuvation Bio (NUVB) has a Buy consensus rating as of Aug 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvation Bio (NUVB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.